|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Fenoldopam#Pharmacology]] |
| {{Fenoldopam}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Description==
| |
| | |
| Corlopam (Fenoldopam Mesylate Injection, USP) is a dopamine D1-like receptor agonist. The product is formulated as a solution to be diluted for intravenous infusion. Chemically it is 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-[1H]-3-benzazepine-7,8-diol methanesulfonate with the following structure:
| |
| | |
| {|
| |
| |[[File:Fenoldopam02.jpg|thumb|800px]]
| |
| |}
| |
| | |
| | |
| | |
| {|
| |
| |[[File:Fenoldopam03.png|thumb|800px]]
| |
| |}
| |
| | |
| | |
| fenoldopam mesylate
| |
| | |
| Fenoldopam mesylate is a white to off-white powder with a molecular weight of 401.87 and a molecular formula of C16H16ClNO3•CH3SO3H. It is sparingly soluble in water, ethanol and methanol, and is soluble in propylene glycol. | |
| | |
| Ampules: Each 1 mL contains, in sterile aqueous solution, citric acid 3.44 mg; fenoldopam mesylate equivalent to fenoldopam 10 mg; propylene glycol 518 mg; sodium citrate dihydrate 0.61 mg; sodium metabisulfite 1 mg.
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CORLOPAM (FENOLDOPAM MESYLATE) INJECTION, SOLUTION [HOSPIRA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df4cd207-c3b8-4008-5290-02f296c2b4a6 | publisher = | date = | accessdate = 26 February 2014 }}</ref>
| |
| | |
| | |
| == References ==
| |
| {{Reflist|2}}
| |
| | |
| {{Sympatholytic antihypertensives}}
| |
| {{Dopaminergics}}
| |
| | |
| [[Category:Benzazepines]]
| |
| [[Category:D1-receptor agonists]]
| |
| [[Category:Phenols]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |